Altasciences Chosen by XORTX Therapeutics, Inc. to Conduct Pharmacokinetic Bridging Study XRX-OXY-101 in Support of Developing New Therapies for Progressive Kidney Disease and Acute Kidney Injury
Laval, Quebec, December 9, 2021 – Altasciences is pleased to have been chosen by XORTX Therapeutics, Inc. to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with COVID-19. XORTX’s novel, proprietary formulations of xanthine oxidase inhibitors are aimed at reducing uric acid levels in order to slow the progression of the genetic disorder ADPKD, and protect against acute kidney injury following COVID-19 infection.
The first of several clinical trials to characterize XORTX’s novel, proprietary formulations of xanthine oxidase inhibitors, its purpose is to determine whether the increased bioavailability of oxypurinol demonstrated for this formulation in preclinical studies will be replicated in humans.
“With a pressing need for better therapeutic options and a global prevalence of kidney disease, we are proud to partner with XORTX for such an important study. We look forward to supporting this innovative company in their goal of bringing a valuable new treatment to the next stage, and getting better drugs to the people who need them, faster,” stated Ingrid Holmes, Vice President, Global Clinical Operations at Altasciences.
Altasciences offers a seamless drug development solution that allows sponsors to work with a single, integrated CRO/CDMO in support of early-phase research, from lead candidate selection to preclinical testing to clinical proof of concept in the most time- and cost-efficient way possible.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com
All You Need to Know About Our Clinical Sites in 11 Minutes
Altasciences’ clinical facilities are dedicated to the conduct of early phase and clinical pharmacology trials in a wide range of therapeutic areas. They are conveniently located close to major metropolitan areas in the U.S. and Canada to ensure a robust participant database.
Our clinics are flexible and adaptable for single or multi-site clinical trials. We have created upscale facilities with accommodations delivering industry best recruitment and retention rates.
- Over 500 beds
- On-site USP 797 certified pharmacies
- Upscale amenities for both short and long-term stays
- 24/7 state-of-the-art safety and security features
- Full-time, dedicated staff
- Design, conduct, analysis, and reporting available on all studies
- Combined database of over 40,000 participants
- Close proximity to major hospitals
Virtually step inside our clinics
by clicking the links below.
| KANSAS CITY, KS | LOS ANGELES, CA | MONTREAL, CANADA |
Request a full virtual tour of our clinical facilities or contact us for more information.
You may also be interested in the following:
- Web page: Phase 1 Clinical Trial Units
- eBook: First-in-Human Solution
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
XORTX Therapeutics Appoints Altasciences as CRO for Clinical Study
Globe Newswire: XORTX Therapeutics Appoints Altasciences as CRO for Clinical Study
Up Close and Personal with Dr. Denise Milovan
Neuroscientist Dr.
Psychedelics — Regulatory Environment Challenges
A History of Public Attitude Towards Psychedelic Drugs
Psychedelic drugs exist within a unique social, legal, and historical environment, with roots in the public imag
Altasciences Announces New Lab Expansion
Altasciences is proud to announce the completion of a second expansion of its ligand binding laboratory to meet the high demand for quality bioanalytical services. The GLP, GCP laboratory was enlarged to include 52 benches for sample analysis, an enhanced space for cell culture and flow cytometry services, additional extraction rooms for handling all types of tissue matrices, a dedicated CL2 room for handling samples and RG2 material, a balance room for critical reagent and solution preparation, and an extraction space for an additional 50 analysts.
With this expansion, Altasciences’ ligand binding assay tripled its square footage and will add to its employee base. Altasciences’ goal is to offer clients the opportunity to leverage the significant knowledge and industry experience of its team of scientific experts to develop strategic bioanalytical testing plans to complement its drug development programs.
Altasciences uses innovative and cost-effective approaches to develop or customize ligand binding assays for the quantitative determination of biologics and small molecules therapeutic products. Altasciences continues to expand its immunogenicity, PK, oligonucleotide and biomarker testing to its already robust preclinical and clinical trial and bioanalysis testing capabilities.
Click here to have a look at the new lab expansion.
Have a question? Speak with an expert today.
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.